The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to ...

Stoke Therapeutics Inc.’s speeded-up timeline for zorevunersen, the antisense oligonucleotide in development with Biogen Inc.

The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to ...

At Praxis, Dr. Devinsky will be part of the group leading clinical strategy and global medical affairs, guiding program architecture, evidence generation, and external scientific engagement as the ...

SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, today announced that its affiliate, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin) will present at the J.P. Morgan's 44th Annual ...

Explore why tau still lacks treatments despite its critical role in Alzheimer's disease and other tauopathies.

NEW YORK – The European Commission has approved a high-dose regimen of Biogen's Spinraza (nusinersen), an antisense oligonucleotide for 5q spinal muscular atrophy (SMA).

The partners will focus on treating Swiss patients with very rare diseases and then use the framework developed to establish similar pathways throughout Europe.

A North Wales police officer who has spent years raising money for others is now fighting for the life of his own son.

Higher intake of certain food preservatives is associated with increased cancer rates, particularly breast and prostate ...

Provincial President Mian Iftikhar Hussain has stressed the need to resolve the ongoing tensions between Pakistan and ...